What is Data Horizon Co., Ltd. stock?

Data Horizon Co., Ltd. Business Introduction

Data Horizon Co., Ltd. (TSE: 3628) is a Japan-based pioneering health-tech firm specializing in the analysis of medical information and the provision of data-driven healthcare services. Based in Hiroshima, the company is widely recognized for its "Medical Cost Optimization" solutions, leveraging Big Data to improve the efficiency of National Health Insurance (NHI) and other public health systems.

Detailed Business Modules

1. Medical Data Analysis Services: This is the core engine of the company. Data Horizon processes vast amounts of "receipt data" (medical claim records) and health check-up results from insurers. By using proprietary algorithms, they identify patients at high risk of lifestyle-related diseases, such as diabetes and chronic kidney disease (CKD), and provide actionable reports to insurers.

2. Health Guidance and Prevention Programs: Based on the data analysis, the company offers targeted intervention programs. This includes sending personalized health notifications to individuals, encouraging them to seek medical consultation before their conditions worsen, thereby preventing severe complications and reducing long-term medical expenditures.

3. Generic Drug Promotion: The company provides services that encourage the switch from brand-name drugs to generic alternatives. By analyzing prescription data, they notify insurers and policyholders of potential savings, contributing directly to the sustainability of the Japanese social security system.

4. PHR (Personal Health Record) Platforms: Through its digital infrastructure, Data Horizon enables individuals to manage their own health data. This fosters a shift toward "self-medication" and proactive health management.

Business Model Characteristics

B2G and B2B Focus: The primary clients are local governments (municipalities) and National Health Insurance associations. The business model is highly stable due to the multi-year nature of public contracts and the increasing government mandate for medical cost reduction.

Data-Driven Recurrence: As the company accumulates more medical data, its analysis becomes more accurate, creating a recurring service model where data insights lead to continuous intervention contracts.

Core Competitive Moat

· Massive Medical Database: Data Horizon possesses one of the largest medical claim databases in Japan, providing a significant barrier to entry for new competitors who lack historical data for algorithm training.
· Proprietary Scoring Logic: The company has developed unique logic for "severity prevention" (preventing the worsening of chronic diseases), which is highly regarded by the Ministry of Health, Labour and Welfare (MHLW).
· Strategic Synergy with DeNA: Following its capital and business alliance with DeNA Co., Ltd., Data Horizon has integrated advanced UI/UX capabilities and consumer-facing digital technology into its professional data services.

Latest Strategic Layout

As of late 2024 and early 2025, Data Horizon is focusing on the "National Health Data Platform." Following its consolidation as a subsidiary of DeNA, the company is integrating its data analysis with DeNA's "kencom" healthcare app to create an end-to-end ecosystem from data diagnosis to user behavior change. They are also expanding into AI-driven predictive modeling for pharmaceutical companies to assist in drug efficacy research.

Data Horizon Co., Ltd. Development History

The history of Data Horizon is a journey from a medical software developer to a national leader in healthcare Big Data.

Development Phases

Phase 1: Foundation and Early Software (1982 - 1990s)
Founded in Hiroshima, the company initially focused on developing medical office systems and software for hospitals and pharmacies. This phase provided the technical foundation for understanding how medical claim data (receipts) is structured.

Phase 2: The Pivot to Data Analysis (2000 - 2010)
Anticipating the aging population crisis in Japan, the company shifted its focus toward using medical data for cost containment. In 2004, it launched its "Generic Drug Notification Service," which became a major hit among insurers. The company listed on the Tokyo Stock Exchange (Mothers) in 2011.

Phase 3: Deepening Prevention Services (2012 - 2021)
The company expanded its repertoire to include "Severity Prevention" programs, particularly for diabetes. This period was marked by the refinement of their data processing engines. In 2014, the Japanese government's "Data Health Plan" initiative provided a massive tailwind, making Data Horizon's services essential for local governments.

Phase 4: The DeNA Alliance and Digital Transformation (2022 - Present)
In 2022, DeNA Co., Ltd. made a tender offer and turned Data Horizon into a subsidiary. This merger combined Data Horizon’s "Medical Big Data" with DeNA’s "Internet/AI Expertise." Today, the company is focused on creating a comprehensive "Data Health" infrastructure for Japan.

Analysis of Success Factors

First-Mover Advantage: Data Horizon entered the medical receipt analysis market long before "Big Data" became a buzzword in Japan.
Policy Alignment: The company’s growth has been perfectly synchronized with Japanese government policies aimed at curbing rising healthcare costs (which exceeded 47 trillion yen in FY2023).
Niche Focus: By focusing specifically on the insurance payer side (the "insured") rather than just the hospital side, they carved out a highly profitable and defensible niche.

Industry Introduction

The healthcare data industry in Japan is at a critical juncture, driven by the world's fastest-aging population and the urgent need for digital transformation (DX) in the medical sector.

Industry Trends and Catalysts

1. The "2025 Problem": Japan's baby boomers are reaching the age of 75+, leading to a surge in medical and nursing care costs. This creates an inelastic demand for cost-saving data solutions.
2. Government Mandates: The MHLW has mandated that all health insurance societies implement "Data Health Plans." This regulatory environment acts as a permanent sales catalyst for Data Horizon.
3. AI and Predictive Analytics: The industry is moving from retrospective data reporting to prospective health forecasting using AI.

Market Data Overview (Estimated)

Competitive Landscape

The landscape consists of several tiers:
· Pure-play Data Firms: Data Horizon and JMDC (Japan Medical Data Center) are the primary leaders. JMDC (backed by OMURON) is a major competitor but focuses more on health insurance societies (corporate), while Data Horizon has a stronger foothold in municipal (public) health insurance.
· IT Giants: NTT Data and Fujitsu provide the hardware/infrastructure but often partner with specialists like Data Horizon for the "logic" of data analysis.
· New Entrants: Startups are entering the PHR space, but they lack the deep historical claim data held by established players.

Industry Position of Data Horizon

Data Horizon holds a dominant position in the municipal National Health Insurance market. Their "Severity Prevention" logic is considered the industry gold standard. Following its integration with DeNA, Data Horizon is no longer just a "back-end" data processor; it has become a "front-end" health service provider, giving it a unique competitive edge over traditional data aggregators.

Data Horizon Co., Ltd. Financial Health Score

The financial health of Data Horizon Co., Ltd. has faced significant challenges in the recent fiscal year due to strategic restructuring and impairment losses. The score reflects a solid asset base but highlights temporary pressure on profitability and cash flow.

3628 Development Potential

Strategic Integration with DeNA Group

The acquisition of DeSC Healthcare remains the primary catalyst for long-term growth. By merging Data Horizon’s medical database with DeNA’s consumer-facing healthcare apps (like kencom), the company is evolving from a pure B2B data provider to a comprehensive health-tech platform. This synergy aims to create a "National Health Database" that supports both local governments and private insurance societies.

Market Expansion: Data-Driven Preventative Medicine

Data Horizon is shifting its focus toward Data Utilization Services. Recent roadmap updates highlight the use of AI to analyze medical "receipt" data to predict disease progression. This is a critical catalyst in Japan’s aging society, as municipalities are increasingly seeking ways to optimize medical expenditures through preventative care.

Recent Business Catalysts (2025-2026)

1. Academic Recognition: In April 2026, research utilizing DeSC’s health big data was published in the prestigious SLEEP journal, and the company received the "Young Investigator Award" at the Japanese Society of Clinical Epidemiology. This validates the scientific value of their data assets.
2. Municipal Adoption: Expansion of the kencom app to new regions, such as Fukushima Prefecture in March 2026, demonstrates steady penetration into local government health promotion initiatives.

Data Horizon Co., Ltd. Pros and Risks

Company Pros (Upside Factors)

- Unique Data Assets: Holds proprietary technology for grouping medical expenses and managing disease stages, which is difficult for competitors to replicate.
- Strong Parent Support: As a subsidiary of DeNA Co., Ltd. (2432), the company has access to significant capital and technological resources for digital transformation (DX).
- Regulatory Tailwind: The Japanese government's push for "Data Health Plans" provides a steady stream of demand from National Health Insurance (NHI) providers.

Company Risks (Downside Factors)

- Short-term Earnings Volatility: The company recently downwardly revised its FY2026 forecast (April 2026) due to delays in large-scale projects and "timing gaps" in order receipts.
- Impairment Risks: Significant "Special Losses" were recorded in 2025 (approx. ¥2.44 billion in impairment losses on goodwill), reflecting the high cost of recent acquisitions.
- Concentration Risk: Heavy reliance on government contracts can lead to lumpy revenue cycles and sensitivity to changes in public health policy.

How Do Analysts View Data Horizon Co., Ltd. and the 3628 Stock?

As of mid-2024, market sentiment toward Data Horizon Co., Ltd. (TYO: 3628)—a specialized provider of medical information systems and health insurance claim data analysis in Japan—reflects a period of strategic transition. Following its integration as a subsidiary of DeNA Co., Ltd., analysts are focusing on the company’s ability to monetize its vast medical database within Japan’s evolving "Data Health" initiative. Here is a detailed breakdown of the analyst perspectives:

1. Institutional Core Views on the Company

Leveraging the DeNA Ecosystem: Most analysts view the capital and business alliance with DeNA as a pivotal turning point. By combining Data Horizon’s expertise in medical big data with DeNA’s strengths in consumer-facing health apps (like Kencom), the company is seen as a frontrunner in the "Pharmacy DX" (Digital Transformation) space. JPMorgan and local Japanese research firms have noted that this synergy is critical for scaling their chronic disease prevention services.

Market Dominance in Health Insurance Analysis: Analysts recognize Data Horizon’s moat in providing automated systems for the review of health insurance claims (Receipts). With the Japanese government aggressively pushing for standardized digital health records and cost-reduction in national healthcare, the company’s specialized algorithms are viewed as "essential infrastructure" for insurers.

Expansion into AI-Driven Preventative Care: There is growing optimism regarding the company's "AI-Health" initiatives. Analysts are monitoring how Data Horizon uses machine learning to predict the risk of severe disease progression (such as diabetes complications), which allows insurers to intervene early and save costs—a high-margin recurring revenue model.

2. Stock Rating and Valuation Trends

Monitoring of the 3628 ticker shows a moderate level of coverage, primarily dominated by Japanese domestic brokerages:
Rating Distribution: The consensus leans toward "Hold" or "Outperform" (Speculative Buy). While analysts agree on the long-term thematic growth of medical data, the stock has experienced volatility due to recent fluctuations in operating margins.

Financial Performance Data: For the fiscal year ending June 2024, analysts are tracking the company's revenue growth, which has shown a steady upward trend, though net income has been pressured by upfront investments in system upgrades and personnel. The Price-to-Sales (P/S) ratio is often cited as being higher than traditional IT services, reflecting the premium placed on its unique medical dataset.

Target Price Estimates: Average target prices suggest a modest upside from current trading levels (approx. ¥500 - ¥700 range), contingent on the successful rollout of new B2B services for pharmaceutical companies.

3. Analyst-Identified Risk Factors (Bear Case)

Despite the positive tailwinds from Japan's aging population, analysts highlight several risks:
Data Privacy and Regulation: Any tightening of Japan’s Act on the Protection of Personal Information (APPI) regarding medical records could slow down the company's data-sharing capabilities. Analysts warn that regulatory compliance costs remain a constant overhead.

Integration Execution: There is "execution risk" regarding the DeNA merger. Analysts are watching whether the corporate cultures can effectively merge to produce new products at the pace the market expects.

Dependency on Government Policy: Much of Data Horizon’s revenue is tied to the budgets of National Health Insurance associations. If the Japanese government shifts its fiscal priorities or slows down the "Data Health Plan" timeline, Data Horizon’s growth trajectory could be significantly impacted.

Summary

The prevailing view on Data Horizon Co., Ltd. is that it is a "high-conviction niche play" in the Japanese healthcare sector. While the stock has faced some selling pressure due to short-term earnings volatility, analysts believe its long-term value is secured by its data assets. For investors, the consensus is that 3628 represents a strategic bet on the digitalization of the Japanese medical system, though patience is required as the DeNA synergy matures.

Data Horizon Co., Ltd. (3628) Frequently Asked Questions

What are the investment highlights of Data Horizon Co., Ltd., and who are its main competitors?

Data Horizon Co., Ltd. is a leader in medical data analysis in Japan, specializing in the "Data Health Plan" business. Its primary investment highlight is its proprietary technology for analyzing health insurance claims data to prevent the aggravation of lifestyle-related diseases. The company has a significant market share among National Health Insurance providers.
Main competitors include JMDC Inc. (4483), which also focuses on medical big data, and Medical Data Vision Co., Ltd. (3902). Unlike its competitors who often focus on hospital data, Data Horizon's strength lies in its deep integration with insurers and local governments.

Is Data Horizon's latest financial data healthy? What are the revenue, net income, and debt conditions?

According to the financial results for the fiscal year ending June 2023 and the interim results for FY2024, Data Horizon has shown a recovery trend. For the full year 2023, the company reported revenue of approximately 3.7 billion JPY. While the company has faced pressure on net income due to increased R&D and integration costs following its capital alliance with DeNA, its equity ratio remains at a stable level (historically above 50%), indicating a manageable debt structure. However, investors should note that net profit margins have been volatile due to strategic investments in system upgrades.

Is the current valuation of 3628 stock high? How do the PER and PBR compare to the industry?

As of the current market cycle, Data Horizon (3628) often trades at a Price-to-Earnings (PER) ratio that is higher than the broader market average, reflecting investor expectations for growth in the health-tech sector. Its Price-to-Book (PBR) ratio typically ranges between 2.5x and 4.0x. Compared to peers like JMDC, Data Horizon's valuation is often seen as more conservative, though it remains sensitive to fluctuations in government healthcare spending and digital transformation (DX) policies in Japan.

How has the stock price performed over the past year compared to its peers?

Over the past 12 months, Data Horizon's stock has experienced significant volatility. While the broader TSE Growth Market index has faced headwinds, 3628 has occasionally outperformed during periods of positive news regarding "Data Health" initiatives. However, compared to large-cap medical tech stocks, Data Horizon has shown higher beta (volatility). It has generally tracked closely with the performance of Medical Data Vision but has lagged behind JMDC in terms of long-term capital appreciation over a three-year horizon.

Are there any recent positive or negative news trends in the industry affecting Data Horizon?

Positive: The Japanese government's ongoing push for the "Medical DX Total Plan" and the mandatory use of My Number Cards for health insurance are major tailwinds. This increases the demand for standardized data analysis services.
Negative: Tightening municipal budgets and rising labor costs for specialized data scientists are potential risks. Additionally, any changes in the Medical Service Fee revisions by the Ministry of Health, Labour and Welfare (MHLW) can impact the procurement cycles of their primary clients.

Have any major institutions recently bought or sold 3628 stock?

The most significant institutional movement in recent years is the strategic partnership with DeNA Co., Ltd., which holds a majority stake (over 50%), making Data Horizon a consolidated subsidiary. This provides strong financial backing but limits the "free float" of the stock. Institutional ownership by domestic investment trusts remains stable, though international institutional participation is relatively low compared to Nikkei 225 constituents. Recent filings show steady holding patterns from major Japanese regional banks and insurance funds interested in the healthcare DX theme.